Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 versus taxane in previously treated HER2-positive advanced gastric cancer
2012-000660-22Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab emtansine in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Roche. Primary endpoint: Overall survival. Started Jul 2012; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2012-000660-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000660-22.